Is the race for the best coronavirus vaccine dominated by the biggest pharmacy companies? It may appear like that. Out of the 5 candidates of coronavirus vaccine developers in the third phase of a clinical trial that might be the top players in the US market, 3 of them are being co-produced by big drug makers.
Admittedly, the big pharmaceutical companies are leading the race of COVID-19 vaccine development. On the other hand, small-scale business enterprises are also participating and doing well in that race. Moderna (NASDAQ: MRNA), as well as Novavax (NASDAQ: NVAX), are presently conducting their clinical trials and they have high possibilities of emerging as massive winners in this race against the deadly virus in the stock market.
Moderna (NASDAQ:MRNA) And Novavax (NASDAQ:NVAX)
Moderna has undoubtedly been enjoying a great start and power over Novavax in the coronavirus vaccine race to the finish line. As Novavax has been conducting its third and final phase of the clinical trial of the COVID-19 vaccine called NVX-CoV2373 in the United Kingdom, NASDAQ: NVAX is yet to start its central study in the US.
On the other hand, NASDAQ: MRNA has already made their announcement of an amazing provisional efficacy outcome that is expected from their third phase of vaccination trial of mRNA-1273. Towards the beginning of the week, biotech had reported that the Moderna vaccine candidate has been revealing an efficacy of 94.5%. This efficacy is way more than many other vaccine candidates, as observed by the analyst of the industry. In fact, NASDAQ: MRNA has been intending to register for authorization for an emergency usage (EUA) for mRNA-1273 in the upcoming weeks itself.
However, we warn you not to keep Novavax out of this race. NASDAQ: NVAX is also expecting the results of NVX-CoV2373 within the end of the month of November in the US. In the month of August, Novavax had reported a premature stage outcome of the clinical trial which was predicted as one of the highest effective vaccines in the market.
Moderna has been able to surpass the difficulties of the several ultra-cold storage necessities required for their vaccine candidate. Nonetheless, the protein-based Novavax vaccine is completely devoid of these storage needs.
On a better and closer look, Novavax has an advantage over Moderna as they have already prepared another vaccine candidate awaiting a late-stage approval very soon. This vaccine has the possibility of combining NVX-CoV2373 with NanoFlu that could lead to a single-shot coronavirus vaccine after the pandemic.
Moderna has no such late-stage vaccine candidate and is solely dependent on mRNA-1273 to acquire their approval.
